Skip to main content

Opioid Discrimination Lawsuit Against Walgreens Dismissed

Opioid Discrimination Lawsuit Against Walgreens Dismissed

Opioid Discrimination Lawsuit Against Walgreens Dismissed

Introduction

A federal court has rejected a proposed class action lawsuit accusing Walgreens Boots Alliance Inc of discriminating against people with disabilities by prohibiting pharmacists from completing high-dose opioid prescriptions.

When requested to fill high-dose opioid prescriptions, a proposed class action lawsuit accused the pharmacy of discriminating against those with impairments. In other headlines, five doctors in West Virginia pled guilty to a pain treatment conspiracy.

The San Francisco district judge's decision came as Walgreens and other drugstore owners faced thousands of lawsuits around the country, accusing them of failing to curb illegal opioid distribution, which leads to drug addiction. It is an epidemic that has killed over 500,000 individuals over the last two decades.

According to federal authorities, the five doctors pled guilty to participating in a painkiller prescription fraud involving clinics in West Virginia and Virginia. From 2010 through 2015, the strategy was linked to the Hope Clinic and involves consuming oxycodone and other prohibited medications for non-medical purposes. Some prescriptions allowed for seven tablets per day, and many Hope sites served an average of 65 or more consumers per day. A 10-hour workday with only one businessman, according to prosecutors in a news release.

According to the Justice Department, a Minnesota man was sentenced to life in prison on Monday for trafficking fentanyl, which killed 11 individuals who thought it was a less hazardous opioid.

At a city public safety committee meeting Monday, the Dallas county district attorney advocated for the Overdose Detection Mapping Application Program in the face of the nation's addiction and overdose crisis, which health experts say has increased fentanyl and overdose problems in recent years. Motivated by the growing prevalence of other synthetic opioids.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Talcum Powder Cancer Settlement Talks Begin Sept. 4

Categories: Talcum

Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…

Tepezza Hearing Loss Trials Delayed Until Aug 2026

Categories: Tepezza

A series of Tepezza hearing loss lawsuits, which were expected to go before juries next year, will now be delayed. The U.S. District Judge overseeing the multidistrict…

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!